Cargando…
Development of therapeutic antibodies for the treatment of diseases
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their hi...
Autores principales: | Lu, Ruei-Min, Hwang, Yu-Chyi, Liu, I-Ju, Lee, Chi-Chiu, Tsai, Han-Zen, Li, Hsin-Jung, Wu, Han-Chung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939334/ https://www.ncbi.nlm.nih.gov/pubmed/31894001 http://dx.doi.org/10.1186/s12929-019-0592-z |
Ejemplares similares
-
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
por: Hwang, Yu-Chyi, et al.
Publicado: (2022) -
Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer
por: Lu, Ruei‐Min, et al.
Publicado: (2019) -
Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
por: Ke, Feng‐Yi, et al.
Publicado: (2020) -
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
por: Kumari, Monika, et al.
Publicado: (2022) -
Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy
por: Kang, Seung Hyun, et al.
Publicado: (2021)